Hormonal Disorders

New research suggests there was a 53% greater 5-year risk of cardiovascular disease in men with type 2 diabetes who received a GnRH agonist for prostate cancer compared with their counterparts who did not receive GnRH agonists.

Our endocrinology month in review spotlights the most popular content from the past month. The top content from July includes hormone therapy guidance from NAMS, a comparison of management practices among Medicare beneficiaries, and a recap of the top approvals from the first half of 2022.

An analysis of data from more than 8400 postmenopausal women with a history of early-stage nonmetastatic, ER-positive breast cancer suggests there was no increase in risk of breast cancer recurrence or mortality observed with use of vaginal estrogen therapy or menopausal hormone therapy.

A study of more than 15,000 patients from a national insurance research database suggests older patients with hypothyroidism had an 81% increase in risk of having dementia compared to their counterparts without hypothyroidism.

Data from Sweden national registers provide insight into the increased risk of adverse outcomes, including fracture, cardiovascular events, and mortality risk, associated with primary hyperparathyroidism as well as the apparent reductions in risk achieved by undergoing parathyroidectomy.

Dr. Gregory Weiss examines a recent study that detailed the risk of cardiovascular disease associated with under- and over-treatment with thyroid hormone therapy.

Our endocrine month in review spotlights the most popular articles from the past month. This month's top articles include the approval of tirzepatide, news from AACE & ATTD, and a pair of podcast episodes.

A systematic review and meta-analysis from AACE 2022 provides an overview of the potential associations between thyroid dysfunction, including both hypothyroidism and hyperthyroidism, and risk of Parkinson disease.

Data presented at AACE 2022 detail levoketoconazole-specific effects observed among patients with endogenous Cushing's syndrome from the phase 3 LOGICS trial.

A retrospective cohort study provides evidence suggesting higher TSH levels were linked to increased lengths of stay and greater readmission risks among patients with hypothyroidism.

On March 29, Antares Pharma announced the FDA granted approval to their oral testosterone replacement therapy option, testosterone udecanoate (TLANDO), for conditions associated with a deficiency or absence of endogenous testosterone or hypogonadism in adult males.

An analysis of nationwide data from Sweden provides an overview of the increased risk of death associated with Cushing's disease was present even after biochemical remission.

The ESTIMABL2 trial indicates a follow-up strategy not involving use of radioiodine was noninferior to ablation strategies with radioiodine for the occurrence of functional, structural, and biologic events up to 3 years after thyroidectomy.

An analysis comparing those who switched against those who did not, results of the study suggest switching levothyroxine generics did not result in a negative impact on TSH levels in adult patients.

In this listicle, which was created for inclusion in the thyroid disorders edition of our Disease State Series, readers will find a curated list of top guidelines for the management of thyroid disorders composed by our editorial team with assistance from Dr. Elizabeth Pearce.

As part of our thyroid disorders installment of the Disease State Series, we have created a list of clinically relevant reviews related to the management of thyroid disorders. Our list includes reviews examining hypothyroidism, hyperthyroidism, thyroid eye disease, and thyroid management during pregnancy.

In this section of the thyroid disorders edition of our Disease State Series, readers will find an aggregate of resources for primary care providers. These resources were curated by our editorial staff with the help of key opinion leaders to not only provide insight and management of thyroid disorders for clinicians but also offer helpful resources to provide patients and caregivers.

An analysis of data from 1860 mother-child pairs suggests presence of abnormal maternal thyroid hormone levels could help in the prediction of behavioral and emotional health problems in male offspring at 4 years of age.

A cross-sectional study of more than 1000 patients suggests presence of MACS in patients with benign adrenal tumors was associated with increased prevalence and severity of hypertension as well as an increase in the likelihood of requiring insulin therapy in type 2 diabetes.

Announced on December 30, the approval of levoketoconazole (Recorlev), a cortisol synthesis inhibitor, is for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative.

Each month, our editorial staff compiles a month in review highlighting the most popular content from the past month. December's month in review features new guidelines, stories on the effect of delayed visits, and more.

A retrospective analysis of data from more than 170 patients with Cushing syndrome and hyperglycemia provides insight into the effects of curative treatment on hyperglycemia among these patients.

A new analysis from UNSW Sydney details the prevalence of thyroid cancers in the next decade attributable to current levels of overweight and obesity among the population in Australia.

A systematic review and meta-analysis suggest presence of hypothyroidism or TAI could have a negative influence on AMH levels among women.

An analysis of more than 25k patients using levothyroxine demonstrates the impact of appointment delays on TSH levels among these patients.

The latest endocrine case report from Brady Pregerson, MD, features a woman in her mid-30s presenting with swollen glands lasting for the past 3 days and an associated sore throat. Can you determine the correct diagnosis?

An analysis of nearly 400 patients suggests undergoing thyroid radiofrequency ablation in ambulatory settings was associated with increased risk of intraoperative, postoperative, and perioperative side effects than those performed in operating room settings.

An analysis of more than 650 thyroid eye disease patients is providing clinicians with insight into the most common comorbidities and risk factors associated with increased disease severity in patients with TED.

An analysis of data from OPTIC and OPTIC-X provide insight into the effects of teprotumumab in longer duration thyroid eye disease and among patients who were nonresponders in the original trial.

Results of a bioavailability, crossover study suggest use of proton pump inhibitors did not interfere with the absorption of levothyroxine sodium oral solution.